Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

2024 October SP Angel N4P Update Note

N4 Pharma's latest report by SP Angel covers exciting developments across key programs and emphasizes the strategic approach in advancing its portfolio for real-world applications.

Nuvec® for IBD: N4 Pharma continues to make progress on an oral drug delivery system targeting inflammatory bowel disease, with preclinical proof-of-concept work expected to kick off by year-end.

ECP105 Orphan Drug Status: A decision from the FDA on Orphan Drug Designation for ECP105 is anticipated in early 2025, potentially providing advantages in the development of the post-surgical anti-fibrotic treatment.

SRI Collaboration: The partnership with SRI International on gene delivery aims to leverage targeted cell delivery for high-precision treatments, with promising advancements already achieved.

Have questions or want to know more? Submit your questions on the hub, and let’s dive deeper into N4 Pharma’s strategic journey!

Disclaimer: Access to research from SP Angel Corporate Finance LLP (“SPA”) via this website is subject to the following terms and conditions. SPA does not deal with individual or private investors (save in connection with corporate finance business). SPA’s research is thus not prepared for private investors and does not take into account any particular investor’s or class of investors’ investment objectives. You are therefore not being granted access to SPA research in your capacity as an investor or SPA client or potential investor or client. You understand that SPA is not offering you any financial service. Members of SPA’s Research department are not permitted to interact with private investors and you should not attempt to contact them.

SP Angel Healthcare Research - N4 Pharma Using the Nuvec and Liptide platforms to develop products in two key disease areas